NCT06454266View on ClinicalTrials.gov

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

July 25, 2024

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

ORM regimen

"The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2"

Trial Locations (1)

315010

The First Affiliated Hospital of Ningbo University, Ningbo

All Listed Sponsors
lead

Ningbo No. 1 Hospital

OTHER

NCT06454266 - First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) | Biotech Hunter | Biotech Hunter